Please login to the form below

Not currently logged in
Email:
Password:

Cancer Drug Fund

This page shows the latest Cancer Drug Fund news and features for those working in and with pharma, biotech and healthcare.

NICE turns down Opdivo for adjuvant melanoma therapy

NICE turns down Opdivo for adjuvant melanoma therapy

NICE turns down Opdivo for adjuvant melanoma therapy. BMS drug currently only licensed treatment in this setting. ... It also says it cannot recommend the drug for use within the Cancer Drugs Fund (CDF) “because… it is not possible to assess whether

Latest news

  • Keytruda achieves cost effectiveness milestone, first to exit Cancer Drugs Fund Keytruda achieves cost effectiveness milestone, first to exit Cancer Drugs Fund

    This means it will now be removed from the ‘managed access’Cancer Drugs Fund (CDF) the first drug to achieve this since the remodelled system was launched two years ago. ... It’s nearest competitor in front line NSCLC treatment is Tecentriq,

  • NICE U-turn on Opdivo for kidney cancer NICE U-turn on Opdivo for kidney cancer

    guidance. Opdivo (nivolumab) is now set to be recommended as a second-line treatment on the NHS in England and Wales almost immediately as the Cancer Drugs Fund will support the ... happy that NICE has made this recommendation for patients with advanced

  • Reformed Cancer Drugs Fund backs its first drug - AZ’s Tagrisso Reformed Cancer Drugs Fund backs its first drug - AZ’s Tagrisso

    Reformed Cancer Drugs Fund backs its first drug - AZ’ s Tagrisso. ... AstraZeneca's Tagrisso (osimertinib) has become the first drug to be supported by the UK's newly-reformed Cancer Drugs Fund (CDF).

  • Pfizer warns against price-cutting after NICE backs Bosulif Pfizer warns against price-cutting after NICE backs Bosulif

    Pfizer warns against price-cutting after NICE backs Bosulif. Cancer drug is the first to be re-appraised form the CDF. ... NICE has approved the first re-appraised drug from the now-defunct Cancer Drugs Fund (CDF) - but Pfizer has warned that companies

  • Imbruvica wins wider European leukaemia licence Imbruvica wins wider European leukaemia licence

    AbbVie and Johnson &Johnson have been granted a European licence for the expanded use of their chemotherapy alternative drug Imbruvica. ... Despite Imbruvica's status as the most requested CLL drug available on the Cancer Drugs Fund (CDF), the

More from news
Approximately 1 fully matching, plus 28 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics